```mermaid
flowchart TD
TLR4["TLR4<br/>Toll-like Receptor 4"]
TLR2["TLR2<br/>Toll-like Receptor 2"]
MYD88["MYD88<br/>Myeloid Differentiation<br/>Primary Response 88"]
TRAF6["TRAF6<br/>TNF Receptor Associated<br/>Factor 6"]
NFKB1["NF-kappaB<br/>Nuclear Factor<br/>Kappa B"]
STING1["STING1<br/>Stimulator of<br/>Interferon Genes"]
NRF2["NRF2<br/>Nuclear Factor<br/>Erythroid 2"]
MTOR["mTOR<br/>Mechanistic Target<br/>of Rapamycin"]
BECLIN1["BECLIN1<br/>Autophagy Regulator"]
BCL2["BCL2<br/>B-cell Lymphoma 2"]
Neuroinflammation["Neuroinflammation<br/>Glial Activation"]
ALS["ALS<br/>Amyotrophic Lateral<br/>Sclerosis"]
MS["Multiple Sclerosis<br/>Demyelinating<br/>Disease"]
Neurodegeneration["Neurodegeneration<br/>Neuronal Loss"]
TLR4 -->|"activates"| TRAF6
TLR2 -->|"activates"| TRAF6
MYD88 -->|"mediates"| TRAF6
STING1 -->|"interacts with"| TRAF6
TRAF6 -->|"activates"| NFKB1
TRAF6 -->|"promotes"| Neuroinflammation
TRAF6 -->|"contributes to"| ALS
TRAF6 -->|"promotes"| MS
TRAF6 -->|"drives"| Neurodegeneration
TRAF6 -->|"regulates"| NRF2
TRAF6 -->|"modulates"| MTOR
TRAF6 -->|"affects"| BECLIN1
TRAF6 -->|"interacts with"| BCL2
NFKB1 -->|"promotes"| Neuroinflammation
Neuroinflammation -->|"leads to"| Neurodegeneration
Traf6 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@liu2023]
<table> [@ye2002]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TRAF6 Protein (TNF Receptor-Associated Factor 6)</th></tr> [@chen2008]
<tr><td><strong>Protein Name</strong></td><td>TRAF6 (TNF Receptor-Associated Factor 6)</td></tr> [@walsh2008]
<tr><td><strong>Gene</strong></td><td>[TRAF6](/genes/traf6)</td></tr> [@landreth2009]
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y4K5](https://www.uniprot.org/uniprot/Q9Y4K5)</td></tr> [@zhou2015]
<tr><td><strong>PDB IDs</strong></td><td>1LB5, 3HCT, 4CGY</td></tr> [@lin2021]
<tr><td><strong>Molecular Weight</strong></td><td>60 kDa (524 amino acids)</td></tr> [@iannitti2016]
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, Plasma membrane, Endosomes</td></tr> [@cheng2015]
<tr><td><strong>Protein Family</strong></td><td>TRAF family (TNF Receptor-Associated Factor)</td></tr>
<tr><td><strong>Expression</strong></td><td>Ubiquitous; high in immune cells, brain, lung, heart</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">447 edges</a></td>
</tr>
</table>
</div>
TRAF6 (Tumor Necrosis Factor Receptor-Associated Factor 6) is a critical signaling adapter and E3 ubiquitin ligase that plays a central role in innate and adaptive immune signaling. Unlike other TRAF proteins that primarily function as adapters, TRAF6 possesses unique E3 ubiquitin ligase activity that catalyzes K63-linked polyubiquitination, a modification essential for activating downstream signaling pathways including [NF-κB](/entities/nf-kb) and MAPKs<sup><a href="#ref1">[1]</a></sup>.
TRAF6 serves as a key signaling node downstream of multiple pattern recognition receptors (PRRs) including Toll-like receptors (TLRs), IL-1 receptor (IL-1R), and various TNF receptor superfamily members. In the central nervous system, TRAF6 is critically involved in microglial activation and neuroinflammation, making it an important therapeutic target for neurodegenerative diseases<sup><a href="#ref2">[2]</a></sup>.
TRAF6 is a 524-amino acid protein with distinct structural domains:
RING Finger Domain: The N-terminal RING finger domain (residues 1-70) contains cysteine residues that coordinate zinc ions and is essential for TRAF6's E3 ubiquitin ligase activity. The RING finger catalyzes the transfer of ubiquitin from an E2 conjugating enzyme to target proteins<sup><a href="#ref3">[3]</a></sup>. This domain distinguishes TRAF6 from most other TRAF proteins, which lack intrinsic enzymatic activity.
Zinc Fingers: Following the RING finger, TRAF6 contains several zinc-finger motifs (C3HC4-type RING and C2H2-type zinc fingers) that contribute to substrate recognition and protein-protein interactions. These zinc fingers help position targets for ubiquitination.
Coiled-Coil Domain: The coiled-coil domain (residues 120-200) mediates TRAF6 trimerization, which is essential for signal transduction. TRAF6 forms trimers upon receptor engagement, bringing together multiple signaling components.
TRAF Domain: The C-terminal TRAF domain (residues 300-500) consists of:
TRAF6 is a central signaling molecule in multiple pathways:
TLR/IL-1R Signaling: TRAF6 is essential for signaling from all TLRs (TLR1-9) and IL-1 receptor family members. Upon ligand binding, TLRs recruit MyD88 and IRAK kinases, which then phosphorylate and activate TRAF6. Activated TRAF6 catalyzes K63-linked ubiquitination of itself and downstream targets<sup><a href="#ref1">[1]</a></sup>.
TAK1 Activation: A critical function of TRAF6 is activation of TAK1 (Transforming Growth Factor-beta-Activated Kinase 1). TRAF6-mediated ubiquitination creates a binding platform for TAB2/TAB3 adaptors, which bring TAK1 into proximity with upstream activators. TAK1 then phosphorylates IKKβ and MAP kinases (JNK, ERK, p38)<sup><a href="#ref4">[4]</a></sup>.
NF-κB Activation: TRAF6 activates both canonical and non-canonical NF-κB pathways:
E3 Ubiquitin Ligase Function: TRAF6 catalyzes K63-linked polyubiquitination on:
In Alzheimer's disease, TRAF6 plays a dual role in microglial activation and neuroinflammation. [Amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques activate [microglia](/cell-types/microglia-neuroinflammation) through TLRs (particularly TLR2, TLR4) and CD36, which recruit TRAF6 to initiate inflammatory signaling<sup><a href="#ref6">[6]</a></sup>. TRAF6-mediated NF-κB and MAPK activation leads to production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), chemokines, and [reactive oxygen species](/entities/reactive-oxygen-species).
Interestingly, TRAF6 also regulates Aβ clearance through mechanisms involving microglial phagocytosis and lysosomal degradation. Genetic studies have identified TRAF6 variants associated with AD risk, suggesting its involvement in disease pathogenesis<sup><a href="#ref7">[7]</a></sup>.
In Parkinson's disease, TRAF6 contributes to neuroinflammation in multiple ways. [α-Synuclein](/proteins/alpha-synuclein) aggregates, mitochondrial toxins, and environmental stressors activate microglia through TLRs and other PRRs, leading to TRAF6-dependent NF-κB activation<sup><a href="#ref8">[8]</a></sup>. Studies in PD models have shown that TRAF6 is upregulated in substantia nigra dopaminergic [neurons](/entities/neurons) and surrounding microglia. Inhibition of TRAF6 signaling reduces microglial activation and provides neuroprotection in animal models.
In ALS, TRAF6 is activated in motor neurons and glial cells by mutant SOD1, [C9orf72](/entities/c9orf72) repeats, and other disease proteins. TRAF6 contributes to inflammatory signaling and has been implicated in the activation of the [NLRP3 inflammasome](/entities/nlrp3-inflammasome)<sup><a href="#ref9">[9]</a></sup>. Genetic deletion of TRAF6 in microglia reduces inflammatory responses and extends survival in ALS mouse models.
In multiple sclerosis, TRAF6 is critical for immune cell activation and the inflammatory cascade that leads to demyelination. T-cell activation, B-cell function, and myeloid cell responses all require TRAF6 signaling. Myeloid-specific TRAF6 deletion reduces EAE severity, making TRAF6 a potential therapeutic target<sup><a name="ref10">[10]</a></sup>.
TRAF6 creates a positive feedback loop in neuroinflammation:
TRAF6 interacts with numerous signaling proteins:
| Interaction Partner | Interaction Type | Functional Significance |
|-------------------|------------------|------------------------|
| MyD88 | Adapter binding | TLR/IL-1R signaling initiation |
| IRAK1/IRAK4 | Kinase complex | Intermediate signaling |
| TAK1 | Ubiquitination target | MAPK and IKK activation |
| TAB2/TAB3 | Adapter binding | TAK1 complex assembly |
| IKKγ/NEMO | Ubiquitination | IKK complex activation |
| TLRs | Receptor binding | Pattern recognition signaling |
| CD40 | Receptor binding | Adaptive immune signaling |
| RANK | Receptor binding | Osteoclast differentiation |
| TRIF | Adapter binding | [TLR4](/entities/tlr4)/TRIF pathway |
| p62/SQSTM1 | [Autophagy](/entities/autophagy) receptor | Selective autophagy |
TRAF6 is a promising therapeutic target for modulating neuroinflammation:
Small Molecule Inhibitors:
The study of Traf6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving TRAF6 Protein discovered through SciDEX knowledge graph analysis: